GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (STU:BPXA) » Definitions » Buyback Yield %

Bellicum Pharmaceuticals (STU:BPXA) Buyback Yield % : 0.00 (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Bellicum Pharmaceuticals's current buyback yield was 0.00%.


Bellicum Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Bellicum Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Buyback Yield % Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.20 -15.36 -83.21 - -

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bellicum Pharmaceuticals's Buyback Yield %

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Buyback Yield % falls into.



Bellicum Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Bellicum Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2022 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 4.996526
=0.00%

Bellicum Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 3.3037562
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2023) data.


Bellicum Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (STU:BPXA) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (STU:BPXA) Headlines

No Headlines